Status:
COMPLETED
Open-Label Study of Safety of H1337 in Healthy Volunteers
Lead Sponsor:
D. Western Therapeutics Institute, Inc.
Conditions:
Glaucoma Open-Angle Primary
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The trial will evaluate the safety of one dose regimen of H-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.
Eligibility Criteria
Inclusion
- Healthy adult male or female subjects
- Subjects in good ocular and systemic health with clinically insignificant medical and ophthalmic history
Exclusion
- Chronic or acute ophthalmic disease in each eye including but not limited to any form of glaucoma, retinal diseases, clinically significant cataract (primary or secondary)
- Recent intraocular surgery in either eye (within 6 months)
- Note: Other inclusion/exclusion criteria apply.
Key Trial Info
Start Date :
September 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 14 2024
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT06572397
Start Date
September 16 2024
End Date
October 14 2024
Last Update
February 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Research Foundation Inc.
Newport Beach, California, United States, 92663